2-(3-phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses
View Patent ↗The invention relates to dihydroquinazolines and methods for the production thereof, the use thereof in the treatment and/or prophylaxis of diseases, in addition to the use thereof in the production of medicaments in the treatment and/or prophylaxis of diseases, especially for use as anti-viral agents, especially against cytomegalo viruses.
1. A medicament comprising a compound of formula (I), or a salt, or a solvate, or a solvate of a salt thereof,
in which
Ar represents aryl which may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of alkyl, alkoxy, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl, amino, alkylamino, aminocarbonyl and nitro,
where alkyl may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of halogen, amino, alkylamino, hydroxyl and aryl,
or two of the substituents on the aryl radical together with the carbon atoms to which they are attached form a 1,3-dioxolane, a cyclopentane ring or a cyclohexane ring, and any third substituent present is selected independently therefrom from the group mentioned,
R 1 represents hydrogen, alkyl, alkoxy, cyano, halogen, nitro or trifluoromethyl,
R 2 represents hydrogen, alkyl, alkoxy, cyano, halogen, nitro or trifluoromethyl,
R 3 represents alkyl, alkoxy, cyano, halogen, nitro or trifluoromethyl
or
one of the radicals R 1 , R 2 and R 3 represents hydrogen, alkyl, alkoxy, cyano, halogen, nitro or trifluoromethyl and the other two together with the carbon atoms to which they are attached form a 1,3-dioxolane, a cyclopentane ring or a cyclohexane ring,
R 4 represents hydrogen or alkyl,
R 5 represents hydrogen or alkyl,
or
the radicals R 4 and R 5 are attached to carbon atoms directly opposing each other in the piperazine ring and form a methylene bridge which is optionally substituted by 1 or 2 methyl groups, in combination with a further active compound.
2. The medicament according to claim 1 , wherein the further active compound is an antiviral active compound.
3. The medicament according to claim 2 , wherein the antiviral active compound is gancyclovir or acyclovir.
4. A method of controlling viral infections in humans and animals, said method comprising administering an antivirally effective amount of a medicament comprising a compound of formula (I) or a salt, or a solvate, or a solvate of a salt thereof,
in which
Ar represents aryl which may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of alkyl, alkoxy, formyl, carboxyl, alkylcarbonyl, alkoxycarbonyl, trifluoromethyl, halogen, cyano, hydroxyl, amino, alkylamino, aminocarbonyl and nitro,
where alkyl may be substituted by 1 to 3 substituents, where the substituents are selected independently of one another from the group consisting of halogen, amino, alkylamino, hydroxyl and aryl,
or two of the substituents on the aryl radical together with the carbon atoms to which they are attached form a 1,3-dioxolane, a cyclopentane ring or a cyclohexane ring, and any third substituent present is selected independently therefrom from the group mentioned,
R 1 represents hydrogen, alkyl, alkoxy, cyano, halogen, nitro or trifluoromethyl,
R 2 represents hydrogen, alkyl, alkoxy, cyano, halogen, nitro or trifluoromethyl,
R 3 represents alkyl, alkoxy, cyano, halogen, nitro or trifluoromethyl
or
one of the radicals R 1 , R 2 and R 3 represents hydrogen, alkyl, alkoxy, cyano, halogen, nitro or trifluoromethyl and the other two together with the carbon atoms to which they are attached form a 1,3-dioxolane, a cyclopentane ring or a cyclohexane ring,
R 4 represents hydrogen or alkyl,
R 5 represents hydrogen or alkyl,
or
the radicals R 4 and R 5 are attached to carbon atoms directly opposing each other in the piperazine ring and form a methylene bridge which is optionally substituted by 1 or 2 methyl groups, in combination with a further active compound.